MHRA shuts down unlicensed cancer drug facility
February 9, 2015Manufacturing and Production, Sales and Marketing Cambridge, GcMAF, MHRA, first immune, globulin component macrophage activating factor
The MHRA has shut down an unlicensed Cambridgeshire plant that was producing a potentially dangerous drug to be sold online. …
New president for ABPI
February 9, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Amgen, Pfizer, Whitehead, emms, john kearney
The Association of the British Pharmaceutical Industry has appointed John Kearney as its new president. Stepping into the role in …
FDA clears Roche eye drug
February 9, 2015Sales and Marketing AMD, DME, FDA, Lucentis, Retina, Roche, eyes, ranibizumab
The US Food and Drug Administration has shown Roche’s eye-condition drug Lucentis the green light to treat patients with diabetic …
Financial round-up: how has pharma fared in 2014?
February 9, 2015Medical Communications, Research and Development, Sales and Marketing
A select look at the latest figures and performance from some of the industry’s big players:MerckQuarter four 2014 sales Sales of …
Centogene appoints chief business officer
February 9, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Péter Adorján, centogene
Dr Péter Adorján has been appointed to the board of German rare disease firm Centogene and thereby extending its board …
Changing our minds about depression
February 9, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Campbell, Lamb, Lundbeck, depression, economist, mind
Alastair Campbell, former Labour spin doctor and depression patient, thinks that mental and physical health should not be seen as …
Sanofi sales lifted by diabetes and rare diseases
February 6, 2015Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4
Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …
NHS reform was ‘distracting and damaging’
February 6, 2015Sales and Marketing CDF, Cameron, NHS, UK, coalition, healthcare, king's fund
Healthcare think tank The King’s Fund has said through a report that organisational changes to the NHS under the coalition …
AstraZeneca looks for revenue boost via Actavis buy
February 6, 2015Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4
AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …
Flu vaccine ineffective against this season’s strain
February 6, 2015Research and Development, Sales and Marketing A(H3N2, Public Health England, UK, Vaccine, WHO, flu, phe
This season’s flu vaccine has provided little protection against the main strain circulating in the UK according to a new …
US hospitals trial Apple’s HealthKit
February 6, 2015Medical Communications, Sales and Marketing Apple, Health Mate, Motion 24/7 Sleeptracker, Samsung, google, healthkit, wearables
A pilot programme for Apple’s mobile health platform HealthKit has been rolled out across a number of US hospitals to …
Martindale Pharma appoints sales director
February 6, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing eric vick, martindale pharma
UK speciality pharma firm Martindale Pharma has appointed Eric Vick to be its group director of international sales. Eric has …
FDA commissioner steps down in March
February 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrew von Eschenbach, FDA, Margaret Hamburg, Obama, Stephen Ostroff, US
The commissioner of the US Food and Drug Administration Dr Margaret Hamburg is to resign from her post at the …
Pharma adverse event FDA reports are inadequate
February 5, 2015Sales and Marketing FDA, Gilead, Solvaldi, US Institute for Safe Medication Practices, pharma, sofosbuvir
Reports of adverse drug events submitted to the FDA by pharma firms are often incomplete and lacking in detail, a …
Pfizer to buy Hospira for $17 billion
February 5, 2015Sales and Marketing Hospira, Humira, Pfizer, acquisition, biosimilars, merger
Pfizer has struck a deal with Hospira to acquire the company in a deal worth around $17 billion. Industry analysts …
Late-stage successes for Amgen and Roche
February 5, 2015Sales and Marketing Amgen, Bendamustine, Gazyva, Genentech, Humira, Levact, Napp, Roche, adalimumab, obinutuzumab
Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …
GSK blames respiratory woes as sales drop
February 5, 2015Sales and Marketing Advair, GSK, GlaxoSmithKline, HIV, ViiV, Witty, anoro ellipta, breo, lovaza, q4, sales
GlaxoSmithKline’s respiratory business has been flagged as the key factor in the firm’s fourth quarter financial misfortunes, as its total …
Pfizer gets early approval for breast cancer drug
February 4, 2015Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib
The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …
Gilead sales soar on back of hepatitis drugs
February 4, 2015Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi
The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …
Half of UK population will get cancer
February 4, 2015Research and Development, Sales and Marketing CDF, CRUK, Cancer, Jevtana, Sanofi, cabazitaxel
New figures from Cancer Research UK (CRUK) suggest that one in two people will develop cancer at some point in …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
